In the latest fracas over the burgeoning market for weight loss drugs, a compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients.
Strive Specialties claimed the drugmakers entered into exclusive agreements with telehealth providers, which were then barred from working with compounders; interfered with relationships that compounders have with payment processors and social media platforms; and regularly disparaged compounded medicines as illegal or unsafe.
In doing so, Lilly and Novo Nordisk “unlawfully restricted competition and directly harmed patients in the U.S. As a result, patients are forced to pay inflated prices and suffer reduced access to [the] medicines, particularly personalized versions of those medicines,” Strive argued in its lawsuit, which was filed in Texas.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
<
Leave a Reply